Principal Financial Group
AGRX

Principal Financial Group’s Agile Therapeutics AGRX Stock Holding History

Principal Financial Group’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9
Closed -$17K – 2677
2021
Q3 		$17K Sell
9
-1
-10% -$2.26K ﹤0.01% 2571
2021
Q2 		$27K Sell
10
-7
-41% -$23.1K ﹤0.01% 2594
2021
Q1 		$72K Sell
17
-1
-6% -$5.41K ﹤0.01% 2439
2020
Q4 		$103K Buy
18
+4
+29% +$23.5K ﹤0.01% 2359
2020
Q3 		$86K Sell
14
-1
-7% -$5.73K ﹤0.01% 2278
2020
Q2 		$83K Buy
+15
New +$77.9K ﹤0.01% 2264

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Principal Financial Group's AGRX Position: Q4 2021 in Review

Principal Financial Group sold out of Agile Therapeutics (AGRX) in Q4 2021, closing a stake of 9 shares — an estimated $17K sold.

Principal Financial Group first reported a position in AGRX in Q2 2020 and held it in 6 quarters. The position peaked at $103K in Q4 2020. 45 funds tracked by Wall St. Rank hold AGRX as of Q4 2021.

  • Principal Financial Group reported no remaining Agile Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Principal Financial Group sold 9 Agile Therapeutics shares in Q4 2021, an estimated $17K.
  • Principal Financial Group first reported a position in Agile Therapeutics in Q2 2020 and held it in 6 quarters.
  • Principal Financial Group's Agile Therapeutics position peaked at $103K in Q4 2020.
  • 45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2021.

Based on Principal Financial Group's 13F filing for Q4 2021, filed 9 Feb 2022.